Non-Small Cell Lung Cancer

China Phase 3 Shows 34% Drop in Death Risk for Experimental Lung Cancer Drug

Regulators and investors will await results from the ongoing global Harmoni-3 trial to determine whether the survival gain and higher bleeding rates apply beyond the China population.